• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

More randomization in phase II trials: necessary but not sufficient.

作者信息

Rubinstein Lawrence, Leblanc Michael, Smith Malcolm A

出版信息

J Natl Cancer Inst. 2011 Jul 20;103(14):1075-7. doi: 10.1093/jnci/djr238. Epub 2011 Jun 27.

DOI:10.1093/jnci/djr238
PMID:21709273
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3139589/
Abstract
摘要

相似文献

1
More randomization in phase II trials: necessary but not sufficient.II期试验中更多的随机化：必要但不充分。
J Natl Cancer Inst. 2011 Jul 20;103(14):1075-7. doi: 10.1093/jnci/djr238. Epub 2011 Jun 27.
2
Randomized phase II trials: a long-term investment with promising returns.随机二期临床试验：一项具有广阔前景的长期投资。
J Natl Cancer Inst. 2011 Jul 20;103(14):1093-100. doi: 10.1093/jnci/djr218. Epub 2011 Jun 27.
3
SOP 09: Statistical design and analysis.标准操作规程09：统计设计与分析。
Onkologie. 2003 Oct;26 Suppl 6:43-7. doi: 10.1159/000075012.
4
Design and endpoints of clinical trials in hepatocellular carcinoma.肝细胞癌临床试验的设计与终点
J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.
5
Optimal designs for two-arm, phase II clinical trial design with multiple constraints.具有多重约束的双臂II期临床试验设计的最优设计
J Biopharm Stat. 2010 Jan;20(1):106-24. doi: 10.1080/10543400903280597.
6
Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting.比较在相同治疗环境中采用相同方案的随机对照 II 期试验和后续 III 期试验的治疗效果。
Eur J Cancer. 2019 Nov;121:19-28. doi: 10.1016/j.ejca.2019.08.006. Epub 2019 Sep 14.
7
Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?2期试验中肿瘤大小的早期平均变化：有效终点还是虚假承诺？
J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. doi: 10.1093/jnci/djm167. Epub 2007 Sep 25.
8
Design of randomized controlled trials.随机对照试验的设计
Circulation. 2007 Mar 6;115(9):1164-9. doi: 10.1161/CIRCULATIONAHA.105.594945.
9
Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.单臂与随机化 II 期癌症临床试验中错误率的比较。
J Clin Oncol. 2010 Apr 10;28(11):1936-41. doi: 10.1200/JCO.2009.25.5489. Epub 2010 Mar 8.
10
[Phases 0, 1 and 2 oncology clinical trials: current questions].[肿瘤学0期、1期和2期临床试验：当前问题]
Bull Cancer. 2010 Jan;97(1):55-63. doi: 10.1684/bdc.2010.1016.

引用本文的文献

1
Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design.在采用单臂两阶段西蒙设计的基于优效性的临床试验中纳入非劣效性分析。
Contemp Clin Trials Commun. 2020 Nov 28;20:100678. doi: 10.1016/j.conctc.2020.100678. eCollection 2020 Dec.
2
A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.随机化在肿瘤学 II 期临床试验应用的观点综述
J Natl Cancer Inst. 2019 Dec 1;111(12):1255-1262. doi: 10.1093/jnci/djz126.
3
Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data.利用既往临床试验和真实世界数据设计和评估外部控制臂。
Clin Cancer Res. 2019 Aug 15;25(16):4993-5001. doi: 10.1158/1078-0432.CCR-19-0820. Epub 2019 Jun 7.
4
To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs.随机化，还是不随机化，这是个问题：利用先前临床试验的数据来指导未来的设计。
Neuro Oncol. 2019 Oct 9;21(10):1239-1249. doi: 10.1093/neuonc/noz097.
5
Do single-arm trials have a role in drug development plans incorporating randomised trials?在纳入随机试验的药物研发计划中，单臂试验有作用吗？
Pharm Stat. 2016 Mar-Apr;15(2):143-51. doi: 10.1002/pst.1726. Epub 2015 Nov 26.
6
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods.基于II期试验中肿瘤测量指标，采用重采样方法预测III期试验总生存结局的临床效用。
J Clin Oncol. 2015 Dec 1;33(34):4048-57. doi: 10.1200/JCO.2015.60.8778. Epub 2015 Oct 26.
7
Pancreatic cancer: why is it so hard to treat?胰腺癌：为何如此难以治疗？
Therap Adv Gastroenterol. 2013 Jul;6(4):321-37. doi: 10.1177/1756283X13478680.
8
Estimation of renal cell carcinoma treatment effects from disease progression modeling.从疾病进展模型评估肾细胞癌的治疗效果。
Clin Pharmacol Ther. 2013 Apr;93(4):345-51. doi: 10.1038/clpt.2012.263. Epub 2012 Dec 27.
9
Choosing phase II endpoints and designs: evaluating the possibilities.选择 II 期终点和设计：评估可能性。
Clin Cancer Res. 2012 Apr 15;18(8):2130-2. doi: 10.1158/1078-0432.CCR-12-0454. Epub 2012 Mar 8.

本文引用的文献

1
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).西地尼布联合 FOLFOX/CAPOX 对比安慰剂联合 FOLFOX/CAPOX 一线治疗转移性结直肠癌的随机、双盲、III 期临床研究（HORIZON II）
J Clin Oncol. 2012 Oct 10;30(29):3596-603. doi: 10.1200/JCO.2012.42.6031. Epub 2012 Sep 10.
2
Randomized phase II trials: a long-term investment with promising returns.随机二期临床试验：一项具有广阔前景的长期投资。
J Natl Cancer Inst. 2011 Jul 20;103(14):1093-100. doi: 10.1093/jnci/djr218. Epub 2011 Jun 27.
3
NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma.英国国家卫生与临床优化研究所（NICE）关于帕唑帕尼用于晚期肾细胞癌一线治疗的指南。
Lancet Oncol. 2011 Mar;12(3):221-2. doi: 10.1016/s1470-2045(11)70042-0.
4
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.一项随机、安慰剂对照、III 期研究，评估一线奥沙利铂为基础的化疗联合 PTK787/ZK 222584（一种口服血管内皮生长因子受体抑制剂）治疗转移性结直肠腺癌患者的疗效。
J Clin Oncol. 2011 May 20;29(15):1997-2003. doi: 10.1200/JCO.2010.29.4496. Epub 2011 Apr 4.
5
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.RIBBON-1：一项针对人表皮生长因子受体 2 阴性、局部复发性或转移性乳腺癌一线治疗的化疗联合或不联合贝伐珠单抗的随机、双盲、安慰剂对照 III 期临床试验。
J Clin Oncol. 2011 Apr 1;29(10):1252-60. doi: 10.1200/JCO.2010.28.0982. Epub 2011 Mar 7.
6
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.评估贝伐单抗在 II 期和 III 期结肠癌中的 III 期临床试验：NSABP 方案 C-08 的结果。
J Clin Oncol. 2011 Jan 1;29(1):11-6. doi: 10.1200/JCO.2010.30.0855. Epub 2010 Oct 12.
7
Randomized phase II trials: misleading and unreliable.随机II期试验：具有误导性且不可靠。
J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20.
8
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.帕唑帕尼治疗进展性、放射性碘难治性、转移性分化型甲状腺癌的疗效：一项 2 期联合研究结果。
Lancet Oncol. 2010 Oct;11(10):962-72. doi: 10.1016/S1470-2045(10)70203-5. Epub 2010 Sep 17.
9
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.三氧化二砷可改善急性早幼粒细胞白血病成人患者的无事件生存和总生存：北美白血病协作组研究 C9710。
Blood. 2010 Nov 11;116(19):3751-7. doi: 10.1182/blood-2010-02-269621. Epub 2010 Aug 12.
10
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).吉西他滨联合贝伐珠单抗对比吉西他滨联合安慰剂治疗晚期胰腺癌患者：癌症和白血病 B 组（CALGB 80303）的 III 期试验。
J Clin Oncol. 2010 Aug 1;28(22):3617-22. doi: 10.1200/JCO.2010.28.1386. Epub 2010 Jul 6.